On October 26, Bayer announced that the State Drug Administration has approved Shu Huabo, the world's first activated coagulation factor XI inhibitor, to reduce the risk of stroke in adult patients with ischemic stroke or high-risk transient ischemic attacks, excluding patients with cardiogenic embolic stroke. Bayer Schwarzenegger's listing application received priority review. It took about half a year from acceptance to approval, and received the first batch in the world in China.

On October 26, Bayer announced that the State Drug Administration has approved Shu Huabo, the world's first activated coagulation factor XI inhibitor, to reduce the risk of stroke in adult patients with ischemic stroke or high-risk transient ischemic attacks, excluding patients with cardiogenic embolic stroke. Bayer Schwarzenegger's listing application received priority review. It took about half a year from acceptance to approval, and received the first batch in the world in China.